- Home
- SCNI vs QLGN Comparison
SCNI vs QLGN Comparison
Compare SCNI & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNI
- QLGN
- Stock Information
- Founded
- SCNI 2003
- QLGN 1996
- Country
- SCNI Israel
- QLGN United States
- Employees
- SCNI N/A
- QLGN N/A
- Industry
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- SCNI Health Care
- QLGN Health Care
- Exchange
- SCNI Nasdaq
- QLGN Nasdaq
- Market Cap
- SCNI 1.9M
- QLGN 2.2M
- IPO Year
- SCNI N/A
- QLGN N/A
- Fundamental
- Price
- SCNI $2.55
- QLGN $3.48
- Analyst Decision
- SCNI
- QLGN
- Analyst Count
- SCNI 0
- QLGN 0
- Target Price
- SCNI N/A
- QLGN N/A
- AVG Volume (30 Days)
- SCNI 18.0K
- QLGN 158.4K
- Earning Date
- SCNI 05-14-2025
- QLGN 05-06-2025
- Dividend Yield
- SCNI N/A
- QLGN N/A
- EPS Growth
- SCNI N/A
- QLGN N/A
- EPS
- SCNI 8.20
- QLGN N/A
- Revenue
- SCNI $452,000.00
- QLGN N/A
- Revenue This Year
- SCNI N/A
- QLGN N/A
- Revenue Next Year
- SCNI N/A
- QLGN N/A
- P/E Ratio
- SCNI $0.30
- QLGN N/A
- Revenue Growth
- SCNI N/A
- QLGN N/A
- 52 Week Low
- SCNI $1.90
- QLGN $2.85
- 52 Week High
- SCNI $8.92
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- SCNI 45.49
- QLGN 52.85
- Support Level
- SCNI $1.90
- QLGN $3.10
- Resistance Level
- SCNI $2.54
- QLGN $4.40
- Average True Range (ATR)
- SCNI 0.29
- QLGN 0.40
- MACD
- SCNI 0.04
- QLGN 0.05
- Stochastic Oscillator
- SCNI 47.71
- QLGN 40.32
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.